A 14-year-old male with ADHD, combined presentation, was started on guanfacine extended-release 1 mg at bedtime eight weeks ago after his parents declined stimulant medication. He was titrated to 3 mg daily over six weeks. At follow-up, his Vanderbilt ADHD Rating Scale completed by his teacher shows a reduction in hyperactivity-impulsivity items from an average of 2.4 to 1.3, but inattention items have only decreased from 2.6 to 2.1. His parents report he is less impulsive and argumentative at home but still has significant difficulty completing homework and organizing school materials. His blood pressure is 100/62 mmHg and heart rate is 64 bpm. He reports mild sedation in the morning that has persisted since the last dose increase. The PMHNP is evaluating the treatment response. Which of the following best represents the appropriate evaluation?